CN105392878A - 用于控制蛋白质中的岩藻糖基化水平的方法 - Google Patents

用于控制蛋白质中的岩藻糖基化水平的方法 Download PDF

Info

Publication number
CN105392878A
CN105392878A CN201480041292.1A CN201480041292A CN105392878A CN 105392878 A CN105392878 A CN 105392878A CN 201480041292 A CN201480041292 A CN 201480041292A CN 105392878 A CN105392878 A CN 105392878A
Authority
CN
China
Prior art keywords
glycoprotein
cell
manganese
disease
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480041292.1A
Other languages
English (en)
Chinese (zh)
Inventor
P·纳伊尔
R·梅拉克德
R·文卡塔拉曼
L·阿迪卡瑞
A·彼哈特纳噶
S·普拉布胡
K·舒克拉
D·巴斯卡
S·德桑
H·V·派
J·E·蒙特罗卡西米洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Biocon Ltd
Original Assignee
Centro de Immunologia Molecular
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Immunologia Molecular, Biocon Ltd filed Critical Centro de Immunologia Molecular
Publication of CN105392878A publication Critical patent/CN105392878A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
CN201480041292.1A 2013-07-23 2014-07-23 用于控制蛋白质中的岩藻糖基化水平的方法 Pending CN105392878A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN3262CH2013 2013-07-23
IN3262/CHE/2013 2013-07-23
IN3265CH2013 2013-07-23
IN3265/CHE/2013 2013-07-23
PCT/IB2014/063348 WO2015011660A1 (en) 2013-07-23 2014-07-23 Methods for controlling fucosylation levels in proteins

Publications (1)

Publication Number Publication Date
CN105392878A true CN105392878A (zh) 2016-03-09

Family

ID=52392808

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480041292.1A Pending CN105392878A (zh) 2013-07-23 2014-07-23 用于控制蛋白质中的岩藻糖基化水平的方法

Country Status (19)

Country Link
US (2) US9856502B2 (enExample)
EP (2) EP3024922A4 (enExample)
JP (1) JP6480926B2 (enExample)
KR (1) KR102062784B1 (enExample)
CN (1) CN105392878A (enExample)
AU (1) AU2014294618B2 (enExample)
BR (1) BR112016001461A2 (enExample)
CA (1) CA2926967C (enExample)
CU (1) CU24312B1 (enExample)
EA (1) EA201690269A1 (enExample)
HK (1) HK1220228A1 (enExample)
MX (1) MX2016001042A (enExample)
NZ (1) NZ716182A (enExample)
PE (1) PE20160218A1 (enExample)
PH (1) PH12016500158A1 (enExample)
SG (1) SG11201600067YA (enExample)
TW (1) TWI621711B (enExample)
WO (1) WO2015011660A1 (enExample)
ZA (1) ZA201601113B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111954719A (zh) * 2018-03-26 2020-11-17 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
CN112752769A (zh) * 2018-08-10 2021-05-04 豪夫迈·罗氏有限公司 用于调节蛋白糖基化的细胞培养策略
CN112779307A (zh) * 2021-01-11 2021-05-11 苏桥生物(苏州)有限公司 一种两阶段调节cho表达外源蛋白糖型的方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0822447A2 (pt) 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
EP3227454B1 (en) * 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US11242401B2 (en) * 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus
WO2018092078A1 (en) * 2016-11-18 2018-05-24 Biocon Limited Rapid and efficient de-glycosylation of glycoproteins
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR102742590B1 (ko) * 2018-04-20 2024-12-16 (주)셀트리온 당단백질의 푸코실레이션을 조절하는 방법
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
CA3117447C (en) * 2018-11-13 2024-06-04 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
JP7469593B2 (ja) * 2018-12-27 2024-04-17 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体を製造する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
CN101970493A (zh) * 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
CN102869784A (zh) * 2010-04-07 2013-01-09 动量制药公司 高甘露糖聚糖

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
AU747898B2 (en) * 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
DE60301953T2 (de) 2002-03-05 2006-07-27 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US10059770B2 (en) * 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970493A (zh) * 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
CN102869784A (zh) * 2010-04-07 2013-01-09 动量制药公司 高甘露糖聚糖

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KONNO Y等: "Fucose content of monoclonal antibodies can be controlled bu culture medium osmolality for high antibody-dependent cellular cytotoxicity", 《CYTOTECHNOLOGY》 *
MOLONEY DJ等: "The O-linked fucose glycosylation pathway: identification and characterization of a uridine diphosphoglucose: fucose-beta1,3-glucosyltransferase activity from Chinese hamster ovary cells", 《GLYCOBIOLOGY》 *
杨洞庭等: "核心岩藻糖基化控制在治疗性抗体研究中的应用", 《生命的化学》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111954719A (zh) * 2018-03-26 2020-11-17 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
CN112752769A (zh) * 2018-08-10 2021-05-04 豪夫迈·罗氏有限公司 用于调节蛋白糖基化的细胞培养策略
CN112779307A (zh) * 2021-01-11 2021-05-11 苏桥生物(苏州)有限公司 一种两阶段调节cho表达外源蛋白糖型的方法
CN112779307B (zh) * 2021-01-11 2022-04-19 苏州药明生物技术有限公司 一种两阶段调节cho表达外源蛋白糖型的方法

Also Published As

Publication number Publication date
JP2016525352A (ja) 2016-08-25
SG11201600067YA (en) 2016-02-26
CU20160008A7 (es) 2016-11-29
WO2015011660A1 (en) 2015-01-29
EP3024922A1 (en) 2016-06-01
EP4282975A2 (en) 2023-11-29
AU2014294618B2 (en) 2019-06-27
US9856502B2 (en) 2018-01-02
EA201690269A1 (ru) 2016-05-31
JP6480926B2 (ja) 2019-03-13
EP3024922A4 (en) 2017-03-29
HK1220228A1 (zh) 2017-04-28
PE20160218A1 (es) 2016-05-09
TW201512396A (zh) 2015-04-01
AU2014294618A1 (en) 2016-02-11
MX2016001042A (es) 2017-01-05
US10308970B2 (en) 2019-06-04
EP4282975A3 (en) 2024-02-28
PH12016500158A1 (en) 2016-04-25
US20180087080A1 (en) 2018-03-29
US20160138065A1 (en) 2016-05-19
NZ716182A (en) 2018-07-27
KR20160036589A (ko) 2016-04-04
KR102062784B1 (ko) 2020-01-07
CA2926967A1 (en) 2015-01-29
ZA201601113B (en) 2017-08-30
BR112016001461A2 (pt) 2017-08-29
TWI621711B (zh) 2018-04-21
CA2926967C (en) 2020-12-08
CU24312B1 (es) 2018-02-08

Similar Documents

Publication Publication Date Title
CA2926967C (en) Methods for controlling fucosylation levels in proteins
Golay et al. Role of Fc core fucosylation in the effector function of IgG1 antibodies
Coënon et al. From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement
Jefferis Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Satoh et al. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Reusch et al. Fc glycans of therapeutic antibodies as critical quality attributes
Jefferis Antibody therapeutics: isotype and glycoform selection
US8080415B2 (en) Modified host cells and uses thereof
US9751942B2 (en) Anti-LAMP5 antibody and utilization thereof
Kaneko et al. Optimizing therapeutic antibody function: progress with Fc domain engineering
US20200148785A1 (en) Pd-l1 and ta-muc1 antibodies
US20090214528A1 (en) Host cell lines for production of antibody constant region with enhanced effector function
Wang et al. The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions
Nimmerjahn Role of Antibody Glycosylation in Health, Disease, and Therapy
TW202010844A (zh) 去岩藻醣基化抗體的製造方法
TW202010842A (zh) 去岩藻醣基化抗體及表現此抗體的細胞株

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1220228

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160309

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1220228

Country of ref document: HK